pancreastatin inhibitor 8

Pancreastatin inhibitor 8 (PSTi8) is a 21-amino acid synthetic peptide (sequence: PEGKGEQEHSQQKEEEEEMAV-amide) developed by the CSIR-Central Drug Research Institute (CSIR-CDRI) as a competitive inhibitor of pancreastatin (PST), a chromogranin A-derived peptide. PSTi8 acts by competing with PST for binding to the glucose-regulated protein 78 (GRP78) receptor, thereby preventing PST-mediated insulin resistance, inflammation, and oxidative stress. Preclinical studies have demonstrated that PSTi8 improves glucose tolerance, insulin sensitivity, and lipid profiles in models of type 2 diabetes, obesity, and polycystic ovary syndrome (PCOS). Additionally, research from the University of Manitoba has investigated PSTi8 in preclinical models of ulcerative colitis, where it regulates colonic mucosal barrier function and epithelial cell regeneration in a sex-dependent manner.

Other names

PST inhibitor peptide-8PSTCΔ8pancreastatin inhibitor peptide-8